Oncoclínicas Medsir Sale Ends a Spanish Dispute for Brazil
BRAZIL · BUSINESS
Key Facts
- —What happened Idengene, a wholly owned Oncoclínicas unit, sold its entire Medsir stake to Spain’s MAJ 3 Capital.
- —The price One euro, or about US$1.18 at 23 September 2026 rates.
- —The catch No real cash comes in, and the company has not stated any gain or loss.
- —What it avoids Future payments of up to €52 million (US$61.2 million) tied to the Spanish investment.
- —Small inflow Part of a €350,000 (US$412,000) convertible loan comes back, earmarked for buying medicines.
- —Bigger picture Oncoclínicas is restructuring about R$5.1 billion (US$998 million) of debt under court protection.
A token price ends a legal fight and cancels payments the company says could have reached €52 million (US$61.2 million).
The Oncoclínicas Medsir sale was announced to the Brazilian market on Tuesday, 22 September 2026. The group’s wholly owned unit Idengene sold its entire stake in Spain’s Medsir to MAJ 3 Capital for €1 (about US$1.18).
What Oncoclínicas Sold in Spain
Medsir is short for Medica Scientia Innovation Research, a Barcelona-based company that designs and runs cancer studies. Oncoclínicas bought 49% of it in March 2022 for €5.75 million (US$6.8 million).
Idengene Medicina Diagnóstica is the Oncoclínicas diagnostics arm that held the shares. The 2022 alliance was meant to bring independent cancer trials to Brazil and the wider region.
That 2022 contract also allowed extra payments of up to €3.5 million (US$4.1 million). It gave Oncoclínicas options to move towards full ownership in later years.
The holding is now gone. MAJ 3 Capital SL holds all of Medsir’s share capital, Oncoclínicas told the market.
Why the Oncoclínicas Medsir Sale Costs One Euro
A symbolic price is common when a seller wants out and wants a dispute closed on the same day. The seller gives up any proceeds and, in exchange, walks away from future commitments.
A one-euro price also says something plain. The seller saw more value in ending the commitments than in keeping the shares.
Oncoclínicas said the agreement ends future payment duties for Idengene and for the parent company. Those duties could have reached €52 million (US$61.2 million).
Euro figures here use a rate of about 0.85 euro to the dollar. That is the rate on 23 September 2026.
Which Arbitration Ended, and Which Did Not
The closed case is the arbitration that the buyer, MAJ 3 Capital, had started. It ended as part of the same agreement, the company said.
A separate arbitration is still running and is not touched by this deal. A request to open it was filed in August 2026 at Brazil’s market arbitration chamber.
That case involves the Josephina III fund and funds run by Latache, over a possible mandatory tender offer. Oncoclínicas has said it is not a party to it.
Brazil’s securities regulator, the CVM, ruled on 25 August 2026 that Centaurus Capital must launch a tender offer for Oncoclínicas shares. It set a 60-day deadline.
The difference matters because both disputes surfaced within weeks of each other. Only the Spanish one is now closed.
How the Deal Fits a Wider Debt Repair
Oncoclínicas filed for out-of-court reorganization in July 2026 to restructure about R$5.1 billion (US$998 million) of unsecured financial debt. A São Paulo court let the case proceed on 4 August 2026.
That ruling paused enforcement on the covered debts for 180 days. The company still needs backing from creditors holding more than half of those claims.
The company said the Medsir exit follows its decision to shed assets outside its core business. In August it also completed the sale of a Saudi joint-venture stake for US$6.55 million.
When it filed in July, the company said creditors holding about 37% of the covered claims had signed up. It must pass half to bind the rest.
It filed an updated draft plan on 26 August 2026 and said talks with creditors were still open. Terms can change before any court approval.
Why This Matters for Expats and Investors in Latin America
Oncoclínicas runs one of Latin America’s largest private cancer-care networks. Its shares and bonds sit in many Brazilian portfolios, sometimes inside funds that foreign residents hold.
The Oncoclínicas Medsir sale removes a possible future bill, but it brings in almost no cash. Treat it as housekeeping, not as a turning point.
The company announced no change to patient services in Brazil. Current operating obligations sit outside the debts covered by the reorganization.
What is not known is whether such disposals will help win creditor support. That vote, not this deal, is the number to watch next.
One caution applies to the headline number. The €52 million (US$61.2 million) was a ceiling on possible payments, not a debt already on the books.
The finance team has also changed. The board elected Maurício Hasson as chief financial officer and investor relations head on 14 September 2026.
For bondholders the practical read is small but positive. One possible claim in euros is off the table, without new cash going out.
What Is Still Not Known
The company did not publish the arbitration’s subject matter, or the settlement terms beyond the closure itself. It gave no revenue or asset figures for Medsir.
It has not said whether the Oncoclínicas Medsir sale will produce a book gain or a loss. That should become clear in the next set of results.
Nothing has been published about what MAJ 3 Capital paid beyond the single euro. Its plans for the Spanish business are also not public.
What Medsir is worth today is not public either. The single-euro price is a settlement figure, not a market valuation.
The company has not said when the buyer opened the arbitration, or where it was heard. Those details were not in the announcement.
Frequently Asked Questions
Frequently Asked Questions
How much did Oncoclínicas get for Medsir?
One euro, about US$1.18. It also gets back part of a €350,000 (US$412,000) convertible loan, to be spent on medicines.
What did the company avoid by selling?
Future payments linked to the investment that it says could have reached €52 million (US$61.2 million). It also closed the buyer’s arbitration.
Does this change cancer care in Brazil?
No change was announced. The deal covers a Spanish holding and a related dispute, not Brazilian clinics.
Sources: Oncoclínicas do Brasil Serviços Médicos communication to the market, 22 September 2026, as reported by Valor Econômico and Finance News; Oncoclínicas material fact of 21 March 2022; Oncoclínicas market communications on its out-of-court reorganization; CVM Colegiado decision of 25 August 2026; MEDSIR.
This article was produced by The Rio Times’ automated newsroom system. How we use AI · Report an error
Read More from The Rio Times